However, as the warfarin/NSAID example shows, downstream selections – such as route (e.g., topical) – can impact the drug-drug interaction. Also, dose/duration may be other important factor in whether or not this is actually a clinically significant interaction. Is it possible to provide the CDS information at an intermediate step between product selection and signing the order?

Existing Wording:

We think that providing information at this stage presents less of a cognitive burden on the clinician and will lead to more effective CDS.